Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | DRD4 | P21917 | 6/20 | 0.48 |
| ▸ | DRD3 | P35462 | 6/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12754475 | 0.93 | DRD2 (0.44) | DRD2DRD4DRD3WDR5ACHE | |
| SCHEMBL13808350 | 0.89 | GRM5 (0.44) | DRD2DRD4DRD3WDR5ACHE | |
| SCHEMBL10000967 | 0.81 | KCNH2 (0.38) | DRD2DRD4DRD3WDR5ACHE | |
| SCHEMBL2628228 | 0.80 | L3MBTL1 (0.59) | DRD2DRD4DRD3WDR5L3MBTL1 | |
| SCHEMBL8274286 | 0.80 | L3MBTL1 (0.59) | DRD2DRD4DRD3WDR5L3MBTL1 | |
| SCHEMBL22224042 | 0.80 | DRD2 (0.50) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL13663829 | 0.80 | CYP2A6 (0.54) | DRD2DRD4DRD3MAPTTDP1 | |
| SCHEMBL16385726 | 0.79 | CA1 (0.58) | ACHEMAPTTDP1MAOB | |
| SCHEMBL14588243 | 0.79 | NQO1 (0.74) | NQO1MAPTTDP1 | |
| SCHEMBL12585056 | 0.78 | DRD2 (0.59) | DRD2DRD4DRD3L3MBTL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183768-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2021011722-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2021-01-21 | — | — | WO | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3039020-B1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
| EP-2935514-B1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
| WO-2016124939-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-11 | — | — | WO | disclosed |
| US-7786106-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| EP-1805170-B1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7544400-B2 | Bimesogenic compounds and flexoelectric devices | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | ASTELLAS PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7504417-B2 | Substituted benzene derivatives or salts thereof | ASTELLAS PHARMA INC. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| EP-1839655-A1 | CTGF EXPRESSION INHIBITOR | Shionogi Co., Ltd. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | DRD2 4763/4885DRD4 4671/4885DRD3 4172/4885 |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MLX, FOXM1, SFXN1 | DRD2 2591/4885DRD4 2609/4885DRD3 2121/4885 |
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | DRD2 1352/4885DRD4 2413/4885DRD3 1515/4885 |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | DRD2 1262/4885DRD4 904/4885DRD3 584/4885 |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | DRD2 4389/4885DRD4 4678/4885DRD3 4517/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | DRD2 139/4885DRD4 181/4885DRD3 161/4885 |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | DRD2 1258/4885DRD4 1219/4885DRD3 1632/4885 |
| US-20160289171-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | DRD2 3470/4885DRD4 3330/4885DRD3 3612/4885 |
| US-20090137498-A1 | such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism | PLG, MGAT3, F11 | DRD2 2971/4885DRD4 2427/4885DRD3 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.